CERO (CERo Therapeutics Holdings) Operating Cash Flow per Share : $-1.30 (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Operating Cash Flow per Share?

CERo Therapeutics Holdings's operating cash flow per share for the three months ended in Mar. 2025 was $-1.30. CERo Therapeutics Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for CERo Therapeutics Holdings's Operating Cash Flow per Share or its related term are showing as below:

CERO's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.2
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

CERo Therapeutics Holdings Operating Cash Flow per Share Historical Data

The historical data trend for CERo Therapeutics Holdings's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Operating Cash Flow per Share Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

-1,682.33

-1,951.50

-48.66

CERo Therapeutics Holdings Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial							-	-	-	-	-1.30

Competitive Comparison of CERo Therapeutics Holdings's Operating Cash Flow per Share

For the Biotechnology subindustry, CERo Therapeutics Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

CERo Therapeutics Holdings Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

CERo Therapeutics Holdings's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	0	/	2.759
	=	0.00

CERo Therapeutics Holdings's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-4.446	/	3.428
	=	-1.30

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30

CERo Therapeutics Holdings Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.